Hualan Pharmaceutical Trade Co., Ltd.
Hualan Pharmaceutical Trade Co., Ltd. (hereinafter the “Company”), being established on February 28, 2005, is a holding subsidiary of Hualan Biological Engineering Inc., specializing in distribution of biological products and vaccines including Human Albumin; Human Immunoglobulin; Tetanus Human Immunoglobulin; Hepatitis B Human Immunoglobulin; Rabies Human Immunoglobulin; IVIG; Factor VIII, Lyophilized; Prothrombin Complex, Lyophilized; Influenza Vaccine (Split Virion), Inactivated; Meningococcal Polysaccharide Vaccine Group ACYW135; Hepatitis B Vaccine made by Recombinant DNA Techniques in Yeast; etc.
The Company realizes an increasing annual distribution scale by using the marketing resources of Hualan Biological Engineering Inc. By 2009, the distribution scale has reached 450 million CNY. "Reputation Based on Quality and Safety” is the operating policy of the company, and each step is strictly operated as per operational procedures. There are cold chains for drug transportation, and the drugs are all the time under electronic monitoring from procurement, storage to shipment. The GPRS system will accurately tell the real-time position and the temperature of the products; and the electronic supervision code is able to track the whole purchase-sell process of every drug, efficiently ensuring the quality and safety of biological products and vaccines during circulation links.
The Company also has a medicinal-background sales force. There are currently 100 and more sales personnel, and 90% of them has an academic background of Associate Degree and above in medical science or pharmacy. There are offices in various provinces, cities and autonomous regions. The after-safe service network covers almost the whole country.
We will always stick to the corporate philosophy of “All for Human Health” and contribute more to human health.
Hualan Biological Bacterin Co., Ltd.
Located in Xinxiang City of Henan Province, Hualan Biological Bacterin Co., Ltd., is a subsidiary company of Hualan Biological Engineering Inc. It covers a field of 180, 000 ㎡, with 55,ooo㎡ building area and over 10,000㎡ classified clean area . The land is divided into the office area, manufacturing area and auxiliary area rationally, which complies with the national GMP and other specifications. In addition, the factory is also designed to meet the WHO GMP specifications. It is one of the largest modern vaccine manufacturing bases in China. The company specializes in the R&D of bacterial vaccines, viral vaccines and genetic engineering vaccines for human use. The manufacturing equipment, QC laboratories, experimental animal center and auxiliary facilities are well designed and equipped with high quality and standard, which enables to maximally meet the demand of vaccine production during the outbreak in a very short period. The company implemented a complete quality management system to ensure the safety and efficacy of each vaccine. The large scale automated cold room has a storage capacity of 100 million vials of vaccines, which combined with many large and mini refrigerated vehicles ensures the timeliness and cold chain requirements for vaccine transportation.
Hualan Biological Bacterin Co., Ltd. is ready to offer the best service and products to the CDCs, and commit itself to build an unbreakable immune Great Wall for the general population.
Hualan Biological Engineering (Chongqing) Co., Ltd.
Hualan Biological Engineering (Chongqing) Co., Ltd. is a wholly-owned subsidiary of Hualan Biological Engineering Inc. in Chongqing Municipality. It is the only plasma product enterprise in Chongqing, and also the largest enterprise of plasma product in China. The company was approved for establishment on August 15, 2007 by the Industrial and Commercial Bureau of Fuling District, and begun for construction at Lidu Industrial Park on August 16. 300 million CNY was invested for the first-stage project. The factory is designed to process normal human plasma 1,000 tons per year, covering an area of 58,600 ㎡ and building area 30,000 ㎡. It mainly product plasma products including human albumin, IVIG, human tetanus immunoglobulin, human immunoglobulin, factor VIII, prothrombin complex, etc. After reaching the full capacity, it will be the largest scale, most species-wide and highest automation degreed manufacturing enterprise of plasma products in China, or even in Asia. Then it will greatly ease the serious domestic shortage of plasma products. The company strives for the product diversity and the expansion of industry chain. For the second-stage project, it will expand to R&D of vaccines and genetic medicines, thus maximally increasing the added value of products.
Hualan Biological Engineering (Chongqing) Co., Ltd., as a key attracting investment project in Chongqing, has been invested almost CNY 300 million, possessing the independent development right of source plasma resources of the city. On March 10, 2009 with the supports of Chongqing Municipal government and Fuling District government as well as the unremitting efforts of Hualan staff, the company successfully passed the inspection and was granted with the drug manufacturing license by Chongqing FDA. The pilot production was completed under the supervision of Chongqing FDA, and the products manufactured were tested qualified by NICPBP. Seven plasma stations are approved for construction by Chongqing normal plasma collection planning, of which Wulong, Zhongxian, Kaixian and Tongnan stations are in use, Wuxi station is pending inspection, Pengshui station is almost completed constructing; and Ba’nan station is being replaced by site selection.
Hualan Biological Engineering (Suzhou) Co., Ltd.
Hualan Biological Engineering (Suzhou) Co., Ltd. is located in Suzhou National New and Hi-Tech Development Zone with a total investment of USD 15 million. It has great geographical advantage for locating in the Yantze River Delta economic circle. The company integrates the R&D, production and distribution of plasma products, genetic engineering products, protein chips and other biological products, and has a processing capacity of 1,200 tons of plasma every year. It passed the GMP certification by SFDA in March 2005, creating a new page in the biopharmaceutical industry in Jiangsu Province.